| 10:30 |
Medtech Investment Dynamics - Pragmatic advice and optimism for 2023?
With a record-breaking benchmark set in 2021, are the slowing IPOs, M&As and a muted performance in SPACs an accurate portrayal of a seemingly quieter MedTech market? A panel of MedTech investors discuss how the current landscape will inform investment in 2023 and how MedTech companies can prepare for the year ahead.
- How are macro factors (geopolitics, ESG, supply chain, inflation) influencing investment decisions, what does this mean for MedTech companies?
- Are timelines for securing investment lengthening and, if so, why? How does this differ between early and late-stage funding, across Europe and the US?
- With money becoming less of a commodity, what markets and device types are receiving attention from investors and how can companies build robust pitches to attract investment?
Moderator: Giles Hamilton, CEO, ODx Innovations
Joachim Rautter, Managing Partner, Peppermint Venture Partners
Rebecca Todd, Investment Director, Longwall Venture Partners
Vivien de Tusch-Lec, General Partner, RYSE Asset Management
   
|
| 14:00 |
Investment within Digital Health & Healthtech: Reviewing the success, growth and funding
- Evaluating the year so far- How does early-stage investment compare to late-stage investment?
- Have the regulatory advancements in Europe affected investment activity in the digital therapeutics and digital health space?
- How do we make Europe a destination of choice for VC Start-up scale up?
- Contrasting US and EU investment landscapes: Looking at the differences, US have higher valuations, raise a lot more capital. Why is that?
- Are we now beyond the hype? The adoption of AI and machine learning in healthcare
Moderator: Tina Tan, Executive Editor, FirstWord HealthTech
Catherine Boule, Managing Partner, Karista
Rabab Nasrallah, Investment Associate, Earlybird Health
Vijay Barathan, Partner, Optum Ventures
Guillem Masferrer, Investment Director, Asabys
    
|
